TAC-001

N/A

Report date: 2024/04/19 11:57:45

First In Class

Base Information

Drug NameTAC-001

Drug Alias NameCD22 targeting TRAAC (Tallac Therapeutics)TAAC-001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionToll like receptor 9 agonistsAnti-CD22

TargetsToll like receptor 9CD22

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

ATC CodeN/A